Geritam D Tablet ER is a combination pharmaceutical formulation containing Tamsulosin 0.4 mg and Dutasteride 0.5 mg, indicated for the management of benign prostatic hyperplasia (BPH). Tamsulosin, an alpha-1 adrenergic receptor antagonist, facilitates the relaxation of smooth muscle in the bladder neck and prostate, thereby improving urine flow and reducing symptoms associated with BPH such as urinary frequency, urgency, and nocturia. Dutasteride, a 5-alpha-reductase inhibitor, acts by blocking the conversion of testosterone to dihydrotestosterone (DHT), a hormone responsible for prostate enlargement. The extended-release (ER) formulation ensures a sustained therapeutic effect, enhancing patient compliance through once-daily dosing. Geritam D Tablet ER is particularly beneficial in patients with moderate to severe symptoms of BPH and those at risk of disease progression. Clinical studies have demonstrated its efficacy in reducing prostate volume, improving urinary flow rates, and decreasing the risk of acute urinary retention and the need for surgical intervention. Common adverse effects may include dizziness, headache, ejaculation disorders, and potential hypersensitivity reactions. Due to its pharmacodynamic profile, caution is advised in patients with hepatic impairment or a history of hypersensitivity to either component. Regular monitoring and consultation with a healthcare professional are recommended to optimize therapeutic outcomes and minimize risks.